Supply of Dulaglutide, sold under the brand name Trulicity, 3mg/0.5ml and 4.5mg/0.5ml solution for injection pre-filled pens will remain out of stock until mid-April 2022.
This follows issuance of a Medicine Supply Notification (MSN) for the medication, used for the treatment of type 2 diabetes, by the Department of Health and Social Care (DHSC).
DHSC stated that Dulaglutide 0.75mg/0.5ml and 1.5mg/0.5ml solution are available and can support an uplift in demand.
In a separate notification, the department has notified MSN for Mesalazine (Asacol) 400mg and 800mg MR gastro-resistant tablets, which would remain out of stock until mid-March 2022.
It stated that Octasa MR 400mg and 800mg tablets are available and can support a full uplift in demand during this period.
In cases where Octasa MR tablets are not considered appropriate, other mesalazine tablets remain available to meet patients’ needs.
